Acute phase of schizophrenia: impact of atypical antipsychotics.
The acute phase of schizophrenia is characterized by the presence of positive, negative and affective symptoms. After recovery, patients still may suffer distressing residual symptoms; they also carry a high risk of relapse which may be associated with further deterioration in their condition. Prompt, early and continued treatment with an effective, well-tolerated antipsychotic agent, is therefore crucial. Typical antipsychotics are poorly tolerated, leading to lack of compliance and relapse. They also lack efficacy in controlling negative and affective symptoms. Atypical compounds such as amisulpride or risperidone are better tolerated. In addition, when compared with either haloperidol or risperidone, amisulpride has been shown to be at least as effective in controlling positive symptoms and significantly superior in alleviating negative symptoms. The onset of action of amisulpride appears more rapid than that of haloperidol. Amisulpride therefore fulfils all the requirements of a first-line agent for the treatment of the acute phase of schizophrenia.